Table 2 Univariate and multivariate Cox regression analyses for PFS and OS

HR (95% CI)

P

HR (95% CI)

P

Sex (men vs. women)

1.245 (0.861–1.801)

0.244

Symptom stage (B vs. A)

2.270 (1.517–3.398)

< 0.001

1.480 (0.974–2.250)

0.066

IPI (HI to high vs. low to LI)

5.002 (3.309–7.562)

< 0.001

3.662 (2.326–5.765)

< 0.001

BM involvement (yes vs. no)

2.664 (1.704–4.162)

< 0.001

1.361 (0.844–2.193)

0.206

Tumor lysis syndrome (yes vs. no)

3.228 (1.631–6.388)

0.001

1.620 (0.802–3.270)

0.178

Renal involvement (yes vs. no)

2.659 (1.382–5.116)

0.003

1.109 (0.563–2.186)

0.765

Chronic kidney disease (yes vs. no)

0.688 (0.219–2.164)

0.522

Bulky disease (yes vs. no)

0.777 (0.470–1.284)

0.325

EASIX (high vs. low)

2.879 (1.998–4.148)

< 0.001

1.551 (1.034–2.326)

0.034

HR (95% CI)

P

HR (95% CI)

P

Sex (men vs. women)

1.297 (0.878–1.916)

0.191

Symptom stage (B vs. A)

2.208 (1.447–3.371)

< 0.001

1.467 (0.947–2.274)

0.086

IPI (HI to high vs. low to LI)

5.104 (3.300–7.894)

< 0.001

3.763 (2.338–6.055)

< 0.001

BM involvement (yes vs. no)

2.484 (1.547–3.988)

< 0.001

1.278 (0.771–2.118)

0.342

Tumor lysis syndrome (yes vs. no)

3.139 (1.522–6.472)

0.002

1.574 (0.747–3.317)

0.233

Renal involvement (yes vs. no)

3.070 (1.587–5.939)

0.001

1.322 (0.667–2.618)

0.423

Chronic kidney disease (yes vs. no)

0.440 (0.109–1.784)

0.250

Bulky disease (yes vs. no)

0.762 (0.448–1.298)

0.317

EASIX (high vs. low)

2.898 (1.975–4.253)

< 0.001

1.567 (1.024–2.398)

0.038